NCT01871428View on ClinicalTrials.gov

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

aleglitazar

150 mcg orally daily

DRUG

placebo

matching aleglitazar placebo orally daily

Trial Locations (7)

33400

Perak

200003

Shanghai

215004

Suzhou

400016

Chongqing

442000

Shiyan

Unknown

Hong Kong

05400

Alor Star

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01871428 - A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy | Biotech Hunter | Biotech Hunter